Last checked at 
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Confirms proposed phase three development pathway and identifies new life cycle management targets for its XF-73 Nasal programme. Says antimicrobial properties of XF-73 Nasal give greater flexibility in the scheduling of surgeries. Adds there is potential to explore new life management indications, particularly in children.
Interim Chief Executive Officer Debra Barker says: "Destiny Pharma is on the right path and that XF-73 Nasal provides a much-needed addition to the armoury against antimicrobial resistance and surgical site infections."
Current stock price: 27.26 pence, up 4.9% on Thursday
12-month change: down 29%
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
